I have had a change of heart recently as to how I would like to see the company proceed down the line. I used to think partnering out P and continuing to build the value of K and B in further trials was the route to go, but I have now changed my view in thinking for the betterment of mankind it would be far better for IPIX to partner out all 3 platforms with a healthy royalty program for any and all future indications.

My reasoning is that each of our drugs has such widespread uses that it is going to take massive amounts of trials to cover the entire spectrum of their respective abilities. That is why I don't want to see just one BP get all platforms. Give them to separate BPs and let each make a fortune by getting them online as quickly as possible.

We all have heard how the scope of B applications has hardly been scratched, we knew that K was suppose to possibly be able to work on 50% of cancers and possibly more in combination forms, and now we are hearing how Prurisol has widespread applications in autoimmune diseases and cancer, namely IL-20 and breast cancer. As time goes on, we keep hearing more and more how each of these drugs are blossoming with additional areas to investigate.

I hope the recent changes at IPIX reflect mgt's belief that they also believe the correct path is akin to what I have described above. It all makes sense to me that it could be the route they have chosen.

We may have been able to make more on the platforms we took further into trials, but that takes time and the path I describe above should put quite a lot of money into all stockholder hands. I think to get a whole platform that BPs will pony up some excellent offers at the current time.

Would love to hear other views as to forward expectations.